Implementation of HIV Retesting During Pregnancy and Postpartum in Kenya: A Cross-Sectional Study.
Journal
Global health, science and practice
ISSN: 2169-575X
Titre abrégé: Glob Health Sci Pract
Pays: United States
ID NLM: 101624414
Informations de publication
Date de publication:
28 02 2022
28 02 2022
Historique:
received:
13
06
2021
accepted:
14
12
2021
entrez:
16
3
2022
pubmed:
17
3
2022
medline:
29
3
2022
Statut:
epublish
Résumé
HIV retesting during pregnancy/postpartum can identify incident maternal HIV infection and prevent mother-to-child HIV transmission (MTCT). Guidelines recommend retesting HIV-negative peripartum women, but data on implementation are limited. We conducted a cross-sectional study in Kenya to measure the prevalence of maternal HIV retesting in programs and HIV incidence. Programmatic HIV retesting data was abstracted from maternal and child health booklets among women enrolled in a cross-sectional and/or seeking services during pregnancy, delivery, or 9 months postpartum in Kenya between January 2017 and July 2019. Retesting was defined as any HIV test conducted by MTCT programs after the initial antenatal care test or conducted as part of retesting policies at/after delivery for women not tested during pregnancy. Poisson generalized linear regression was used to identify correlates of programmatic retesting among women enrolled at 9 months postpartum. Among 5,894 women included in the analysis, 3,124 only had data abstracted and 2,770 were enrolled in a cross-sectional study. Overall prevalence of programmatic HIV retesting was higher at 6 weeks (65%) and 9 months postpartum (72%) than in pregnancy (32%), at delivery (23%) and 6 months postpartum (28%) ( Maternal retest coverage was high at 6 weeks and 9 months postpartum but low during pregnancy. Strategies to ensure high retesting coverage and detect women with incident maternal HIV infection are needed.
Identifiants
pubmed: 35294386
pii: GHSP-D-21-00451
doi: 10.9745/GHSP-D-21-00451
pmc: PMC8885347
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : K01 AI116298
Pays : United States
Organisme : NICHD NIH HHS
ID : P2C HD042828
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NICHD NIH HHS
ID : R24 HD042828
Pays : United States
Informations de copyright
© Penumetsa et al.
Références
PLoS One. 2010 Jul 19;5(7):e11581
pubmed: 20657834
Trop Med Int Health. 2015 Mar;20(3):277-83
pubmed: 25418130
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):467-473
pubmed: 30148731
BMC Infect Dis. 2019 May 9;19(1):398
pubmed: 31072332
J Infect Dis. 2009 Sep 1;200(5):682-6
pubmed: 19627245
Scand J Public Health. 2006;34(3):272-8
pubmed: 16754585
J Acquir Immune Defic Syndr. 2020 Aug 1;84(4):365-371
pubmed: 32195747
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):417-25
pubmed: 22193774
J Int AIDS Soc. 2021 Apr;24(4):e25686
pubmed: 33787064
J Int AIDS Soc. 2017 Dec;20(4):
pubmed: 29236362
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25293
pubmed: 31321884
AIDS. 2020 Apr 1;34(5):761-776
pubmed: 32167990
BMJ. 2010 Dec 22;341:c6580
pubmed: 21177735
PLoS One. 2018 Dec 28;13(12):e0209782
pubmed: 30592749
S Afr Med J. 2007 Mar;97(3):194-9
pubmed: 17440667
J Int AIDS Soc. 2020 Jan;23(1):e25441
pubmed: 31997583
Lancet HIV. 2020 Jan;7(1):e38-e48
pubmed: 31813837
Br J Ind Med. 1993 Sep;50(9):861-2
pubmed: 8398881
N Engl J Med. 1991 Aug 29;325(9):593-8
pubmed: 1812850
AIDS. 2019 Jul 1;33(8):1369-1378
pubmed: 30932954
AIDS. 2009 Jun 19;23(10):1255-9
pubmed: 19455017
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218823530
pubmed: 30798664
J Int AIDS Soc. 2019 Apr;22(4):e25271
pubmed: 30958644